Therapeutic Response

BRAF p.V600K status confers therapeutic sensitivity to Binimetinib in combination with Encorafenib in patients with Melanoma.

Statements

Source and description
Mektovi (binimetinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Braftovi (encorafenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to encorafenib in combination with binimetinib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.
Mektovi (binimetinib) [product monograph]. HC. Health Canada approved binimetinib, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.